Short answer
Entrada Therapeutics, Inc. (TRDA) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4/full-year 2025 earnings press release issued Feb 26, 2026: full financial details in Exhibit 99.1.
Entrada Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4/full-year 2025 earnings press release issued Feb 26, 2026: full financial details in Exhibit 99.1
- CEO Dipal Doshi signed filing, confirming current leadership in place at Entrada Therapeutics (TRDA)
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Entrada Therapeutics, Inc. 8-K filings
Get the next TRDA 8-K as it lands
Follow TRDA for push alerts, or ask the research agent what this filing means.